LMAT Form 4: Director Roush exercises 7,500 options; disposes of 7,500 shares in Aug 2025
Rhea-AI Filing Summary
John A. Roush, a director of LeMaitre Vascular (LMAT), exercised stock options to acquire 7,500 common shares at an exercise price of $37.29 on 08/08/2025 and 08/11/2025, as reported in Table II. The form states these option exercises converted derivative holdings into common stock.
Roush also sold a total of 7,500 shares across transactions on 08/08/2025 and 08/11/2025 at reported weighted-average prices of $93.4872, $92.783 and $91.8181, with execution ranges between $91.38 and $94.00. Following these transactions, the reporting person beneficially owned 2,916 shares of LeMaitre Vascular.
Positive
- Exercised options to acquire 7,500 common shares at an exercise price of $37.29
- Transaction details include weighted-average sale prices and execution ranges, enabling quantification of proceeds
- Ending beneficial ownership clearly reported as 2,916 shares
Negative
- Reported sales of 7,500 shares by the reporting person on 08/08/2025 and 08/11/2025
- Sales executed at weighted-average prices between $91.8181 and $93.4872, reducing direct holdings to 2,916 shares
Insights
TL;DR: Director exercised options and sold the resulting shares, ending with 2,916 shares beneficially owned.
The filing documents option exercises totaling 7,500 shares at a $37.29 exercise price and contemporaneous sales of 7,500 shares at weighted-average prices reported between $91.8181 and $93.4872. These transactions are routine equity plan-related activities documented on Form 4 and do not, on their face, indicate a change in control or a material corporate event. The reported exercise and sale quantities and prices are sufficient for investors to quantify insider liquidity and remaining direct ownership of 2,916 shares.
TL;DR: Insider exercised options and sold shares; net reporting position is 2,916 shares, with executed sale prices in the low $90s.
The report shows option exercises on 08/08/2025 and 08/11/2025 that converted derivative securities into common stock and immediate sales recorded the same days. The filing discloses weighted-average sale prices and execution ranges ($91.38–$94.00), providing clear data to estimate gross proceeds and remaining insider stake. Without outstanding share count or company-level context in this filing, the impact on capitalization and float cannot be determined from this document alone.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 6,561 | $0.00 | -- |
| Exercise | Common Stock | 6,561 | $37.29 | $245K |
| Sale | Common Stock | 4,987 | $92.783 | $463K |
| Sale | Common Stock | 1,574 | $91.8181 | $145K |
| Exercise | Stock Option (Right to Buy) | 939 | $0.00 | -- |
| Exercise | Common Stock | 939 | $37.29 | $35K |
| Sale | Common Stock | 939 | $93.4872 | $88K |
Footnotes (1)
- Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $93.025 to $94.00. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $92.21 to $93.20. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $91.38 to $92.14. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. This option is fully vested and exercisable.
